Список литературы

Поставить закладку

Фомин И. В. Артериальная гипертония в Российской Федерации – последние 10 лет. Что дальше? Сердце. 2007;6 (3):1–6.
Ситникова М. Ю., А. В. Юрченко, Е. А. Лясникова, М. А. Трукшина, Р.А. Либис, В.Ю. Кондратенко, Дупляков Д.В., Хохлунов С.М., Е. В. Шляхто. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология, 2015; 55:10, стр.13 – 21.
Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф. Т. и соавт.] – М.: ГЭОТАР-Медиа, 2010. – c. 7–77
Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24 (5):442–463.
Lam C.S.P., Solomon S.D. The middle child in heart failure: heart failure with mid- range ejection fraction (40–50%). Eur J Heart Fail 2014; 16:1049–1055.5
Щербинина Е.В., Бадин Ю.В., Вайсберг А.Р., и.др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998–2007 гг.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2007 год» – М., 2007. – с. 38.
Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В. Гендерные различия в распространенности сердечно-сосудистых заболеваний (данные когортного исследования репрезентативной выборки Нижегородской области 1998–2002 гг.). Проблемы женского здоровья. 2006;1 (1):37–40
McAlister F.A., Teo K.K., Taher M. et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999; 138 (1 Pt 1):87– 94.
Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник, 2016; № 2:3-33
McMurray J. Clinical practice. Systolic heart failure. N Engl J Med. 2010; 362 (3):228– 238
Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneﬁciaries, 1998–2008. JAMA. 2011; 306 (15):1669–1678
Dunlay S.M., Redﬁeld M.M., Weston S.A. et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009; 54 (18):1695–1702.
Hogg K., Swedberg K., McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004;43 (3):317–327.
Агеев Ф.Т. Влияние современных медикаментозных средств на течение заболевания «качество жизни» и прогноз больных с различными стадиями хронической сердечной недостаточности. Автореф. Дисс. Докт., Москва, 1997.
Senni M., Gavazzi A., Oliva F., at al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Intern J Cardiol 2014;173: 163-9.
Cowie M.R., Fox K.F., Wood D.A. et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002; 23 (11):877–885.
Беленков Ю.Н., Овчинников А.Г., Агеев Ф.Т., Сербул В.М. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная терапия и профилактика 2008; №2:98-108.
Овчинников А.Г., Агеев Ф.Т., Свирида О.Н. Патогенетический подход к терапии пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Кардиологический вестник 2011; №1: 33-39.
Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006; 27 (1):65–75.
Komajda M., Carson P.E., Hetzel S. et al. Factors associated with outcome in heart failure with preserved ejection fraction: ﬁndings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011; 4 (1):27–35.
Ketchum E.S., Levy W.C. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011; 54 (2):86–96.
Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation. 1993; 88 (1):107–115.
Даниелян М. О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения). Автореф. дис. канд. мед.наук. Москва. 2001
Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998–2002 годов.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2005 год» – М., 2005. – с. 31–32
Якушин С.С., Смирнова Е.А., Лиферов Р.А. Выживаемость больных хронической сердечной недостаточностью (данные когортного исследования репрезентативной выборки населения Рязанской области)// Сердечная недостаточность. 2011; 12 (4):218- 221.
Wedel H., McMurrayJ.J., LindbergMetal. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic peptide. Eur J Heart Fail. 2009; 11 (3):281–291
Allen L.A., Felker G.M., Pocock S. et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11 (2):170–177.
Jackson C.E., Solomon S.D., Gerstein H.C. et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374 (9689):543–550.
Felker G.M., Allen L.A., Pocock S.J. et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007; 50(1):40–47.
Беленков Ю. Н., Фомин И. В., Мареев В. Ю. и др. Первые результаты Российского эпидемиологического исследования
Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность 2004;5 (1):4–7.
Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность 2006;7 (1): 112–115.
Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use? QJM 1997; 90: 335–339
Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13:1–207
Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13:518–527
Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006; 11:95–107;
Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons KGM, Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124: 2865–2873
Weingärtner O, Hasan T, Böhm M.Pathophysiology and differential diagnosis of dyspnea Herz. 2004 Sep; 29(6):595-601. doi: 10.1007/s00059-004-2594-0.
Fries R.Differential diagnosis of leg edema. MMW Fortschr Med. 2004 Apr 15; 146(16):39-4.
Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013 May; 6(3):606-19. doi: 10.1161/HHF.0b013e318291329a
Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 3; 126(1):65-75. doi: 10.1161/CIRCULATIONAHA.111.080770.
Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009 Jun 23; 119(24):3070-7. doi: 10.1161/CIRCULATIONAHA.108.815944
Ощепкова Е.В., Лазарева Н.В., Сатлыкова Д.Ф., Терещенко С.Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология 2015. Т. 55. № 5. С. 22-28.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inﬂammation. J Am Coll Cardiol 2013 Jul 23; 62(4):263-71. doi: 10.1016/j.jacc.2013.02.092.
Redﬁeld MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2017 Mar 2; 376(9):897. doi: 10.1056/NEJMc1615918.
Paulus WJ, Dal Canto E. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC Heart Fail 2018 Jan;6(1):1-7. doi: 10.1016/j.jchf.2017.07.012.
Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, Chaanine AH, Agarwal SK. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2014 Dec; 11(4):354-65. doi: 10.1007/s11897-014-0223-7.
Liu M, Fang F, Yu CM. Noncardiac Comorbidities in Heart Failure With Preserved Ejection Fraction—A Commonly Ignored Fact. Circ J 2015; 79(5):954-9. doi: 10.1253/circj.CJ- 15-0056.
Dunlay SM, Roger VL, Redﬁeld MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017 Oct; 14(10):591-602. doi: 10.1038/nrcardio.2017.65.
Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A., Cowie M.R., McMurray J.J.V., Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350:h910.
Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K., McDonagh T., Hardman S.M.C., Dargie H.J., Cowie M.R. The diagnostic accuracy of plasma BNP and NTpro мозговой натрийуретический пептид in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7:537–541.
Fuat A., Murphy J.J., Hungin A.P.S., Curry J., Mehrzad A.A., Hetherington A., Johnston J.I., Smellie W.S.A., Duffy V., Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56:327–333.
Yamamoto K., Burnett J.C., Bermudez E.A., Jougasaki M., Bailey K.R., Redﬁeld M.M. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000; 6:194–200.
Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349–1353.
Krishnaswamy P., Lubien E., Clopton P., Koon J., Kazanegra R., Wanner E., Gardetto N., Garcia A., DeMaria A., Maisel A.S. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274–279.
Kelder J.C., Cramer M.J., Verweij W.M., Grobbee D.E., Hoes A.W.Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. JCardFail 2011; 17: 729–734.
Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386–391.
McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 2003;41: 571–579.
Jankowska EA , von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deﬁciency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34:816–826.
Jankowska EA , Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJV, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J 2013; 34:827–834
Damman K , Valente MAE, Voors AA, O"Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35:455–469.
Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J 2014; 35:416–418;
Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 2009; 6:272–280.
Aguilar D , Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54:422–428.
Ewid M., Sherif H., Allihimy A.S. et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020; 13: 178. doi: 10.1186/s13104-020-05031-3.
Wannamethee S.G., Whincup P.H., Shaper A.G. Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012.
Poelzl G., Eberl C., Achrainer H. et al. Prevalence and prognostic signiﬁcance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail. 2009.
Ess M., Christine Mussner-Seeber K., Siegfried Mariacher S. et al. γ- Glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure.J Card Fail. 2011.
Yamazoe M., Mizuno A., Nishi Y., Niwa K., Isobeet M. Serum alkaline phosphatase as a predictor of worsening renal function in patients with acute decompensated heart failure.J Cardiol. 2016.
Shamban L., Patela B., Williamsaet M. et al. Signiﬁcantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure. Gastroenterology Res. 2014.
Rhee C.M., Curhan G.C., Alexander E.R. et al. Subclinical Hypothyroidism and Survival: The Effects of Heart Failure and Race J Clin Endocrinol Metab. 2013 Jun; 98(6):2326-36. doi: 10.1210/jc.2013-1039.
Pingitore A., Landi P., Taddei M.C. et al. Triiodothyronine levels for risk stratiﬁcation of patients with chronic heart failure. Am J Med. 2005; 118:132–136. doi: 10.1016/j.amjmed.2004.07.052.
Passino C., Pingitore A., Landi P. et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure.J Card Fail. 2009; 15:35–40. doi: 10.1016/j.cardfail.2008.08.008.
Felipe Martinez. Thyroid hormones and heart failure. Heart Failure Reviews volume 21, pages361–364(2016).
Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am CollCardiol, 2003, 2(11): 1933-1940
Cappola A.R., Fried L.P., Arnold A.M. at al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006; 295:1033–1041. doi: 10.1001/jama.295.9.1033
Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic signiﬁcance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.
Khunti K, Squire I, Abrams KR, Sutton AJ.Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail. 2004 Aug;6(5):571-6. doi: 10.1016/j.ejheart.2004.03.013.
Davie A.P., Francis C.M., Love M.P., Caruana L., Starkey I.R., Shaw T.R., Sutherland G.R., McMurray J.J. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312:222.
Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002;112:437–445.
Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008; 101: 465–473.
Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. JAm Coll Cardiol. 2007; 50:381–396.
Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999; 33:164– 170.
Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009; 15: 586– 592.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O"Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Jul 11;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep; 27(9):911-39. doi: 10.1016/j.echo.2014.07.012.
Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE, Olson JJ, Troughton RW. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015 Jan; 28(1):40-56. doi: 10.1016/j.echo.2014.09.009.
EchoNoRMAL (Echocardiographic Normal Ranges Meta-Analysis of the Left Heart) Collaboration. Ethnic-Speciﬁc Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging 2015;8: 656-65.
Muraru D,Badano LP, Peluso D, Dal Bianco L, Casablanca S, Kocabay G, et al. Comprehensive analysis of left ventricular geometry and function by three-dimensional echocardiography in healthy adults. J Am Soc Echocardiogr 2013;26: 618-28.
Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging 2014;15:680-90.
Alherbish, A., Becher, H., Alemayehu, W., Paterson, D. I., Butler, C. R., Anderson, T. J. (2018). Impact of contrast echocardiography on accurate discrimination of speciﬁc degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. doi:10.1111/echo.14152
Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3- dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59: 1799-808.
Goldenberg I., Moss A.J., Hall W.J., et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 124 (14):1527- 1536
Thavendiranathan P., Liu S., Datta S., et al. Automated quantiﬁcation of mitral inﬂow and aortic outﬂow stroke volumes by three-dimensional real-time volume color-ﬂow Doppler transthoracic echocardiography: comparison with pulsed-wave Doppler and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2012; 25 (1):56-65.
Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005 Mar; 26(6):607-16.
Hoffmann R, Barletta G, von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C, et al. Analysis of left ventricular volumes and function—a multicenter comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast enhanced 2D and 3D echocardiography. J Am Soc Echocardiogr 2014; 27:292-301
Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H., Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review. J Am Coll Cardiol 2014; 63:2751–2768
Mignot A, Donal E, Zaroui A, Reant P, Salem A, Hamon C, et al. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J Am Soc Echocardiogr 2010; 23: 1019-24.
Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 2013; 26:185-91.
T. Stanton, R. Leano, T.H. Marwick: Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009;2 (5):356-364.
M. Bansal, G.Y. Cho, J. Chan, et al. Feasibility and accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr 2008; 21:1318-1325
Nagueh S., Smiseth O., Appleton C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29:277-314
Hawkins N.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.
Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P, Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL, Velazquez EJ, Cleland JGF. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. J Am Coll Cardiol 2015;66:2092–2100.
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF, Investigators FS. Fractional ﬂow reserve vs. angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360(3):213 – 224
Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Seraﬁno L, Van Praet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, Barbato E. Fractional ﬂow reserve-guided vs. angiography-guided coronary artery bypass graft surgery. Circu- lation 2013;128(13):1405 – 1411.
Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res 2011;4:416–424.
Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM. F-18- ﬂuorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002–2012.
Gonza´lez-Lo´pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–2594.
S. Longhi, P.L. Guidalotti, C.C. Quarta, et al. Identiﬁcation of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. J Am Coll Cardiol Img, 7 (2014), pp. 531-532
S. Bokhari, A. Castaño, T. Pozniakoff, et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. Circ Cardiovasc Imaging, 6 (2013), pp. 195-201
W.A. Aljaroudi, M.Y. Desai, W.H. Tang, et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol, 21 (2014), pp. 271-283.
Saric M, Armour AC, Arnaout MS, Chaudhry FA, Grimm RA, Kronzon I, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016 Jan;29(1):1-42. doi: 10.1016/j.echo.2015.09.011.
Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/ SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Coll Cardiol. 2011;57:1126–1166
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239
Abhishek Khemka , Stephen G Sawada Dobutamine echocardiography for assessment of viability in the current era. Curr Opin Cardiol. 2019 Sep;34(5):484-489. doi: 10.1097/HCO.0000000000000658.
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R. Identiﬁcation of therapeutic beneﬁt from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6:363–372.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617–1625.
deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol 1995;75:191-4
Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, et al. Outcome after aortic valve replacement for low-ﬂow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol 2009;53:1865- 73
Clavel MA, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, et al. Predictors of outcomes in low-ﬂow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation 2008;118(14 Suppl):S234-42.
Garnier F, Eicher J-C, Jazayeri S, Bertaux G, Bouchot O, Aho L-S, Wolf J-E, Laurent G. Usefulness and limitations of contractile reserve evaluation in patients with low-ﬂow, low- gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail 2014;16:648–654.
Erdei T, Smiseth OA, Marino P, Fraser AG. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail 2014;16:1345–1361.
Donal E, Lund LH, Oger E, Reynaud A, Schnell F, Persson H, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging 2016;17:106–113
Borlaug B., Nishimura R., Sorajja P., et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588―95
Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, Scherer M, Bellinger R, Martin A, Benton R, Delago A, Min JK. Diagnostic performance of 64- multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial, J Am Coll Cardiol , 2008, vol. 52 (pg. 1724-1732).
Paech DC, Weston AR. A systematic review of the clinical effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of suspected coronary artery disease, BMC Cardiovasc Disord , 2011, vol. 11 pg. 32
Goldstein JA Gallagher MJ O"Neill WW Ross MA O"Neil BJ Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007;49:863–871.
Hoffmann U Truong QA Schoenfeld DA Chou ET Woodard PK Nagurney JT Pope JH Hauser TH White CS Weiner SG Kalanjian S Mullins ME Mikati I Peacock WF Zakroysky P Hayden D Goehler A Lee H Gazelle GS Wiviott SD Fleg JL Udelson JE. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012;367:299–308.
Windecker S., Kolh P., Alfonso F., Collet J-P., Cremer J., Falk. V, Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F-J., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J-S., Marx N., Opie L.H., Pﬁsterer M., Prescott E., Ruschitzka F., Sabate´ M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J.M., Zamorano J.L.,Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P.,Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Valgimigli M.,Claeys M.J., Donner-Banzhoff N., Frank H., Funck-Brentano C., Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Husted S., James S.K., Kervinen K.,Kristensen S.D., Maggioni A. Pietro, Pries A.R., Romeo F., Ryde´n L., Simoons M.L., Steg P.G., Timmis A., Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949–3003.
Rofﬁ M., Patrono C., Collet J-P., Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST- segment elevation. Eur Heart J 2015; ehv320
Sousa PA, Bettencourt N, Dias Ferreira N, Carvalho M, Leite D, Ferreira W, de Jesus I, Gama V. Role of cardiac multidetector computed tomography in the exclusion of ischemic etiology in heart failure patients. Rev Port Cardiol. 2014 Oct;33(10):629-36
Hundle WG, Blumke D, Bogaert JG, et al. Society for cardiovascular magnetic resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn reson 2009; 11:5
Kramer C, Barkhausen J, Flamn SD, et al. Standardised cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson, 2008; 10:35
Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial ﬁbrosis. European heart journal cardiovascular Imaging. 2015; 16:14–22.
Gulati A, Jabbour A, Ismail TF, et al. Association of ﬁbrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013; 309:896– 908.
Puntmann VO, Carr-White G, Jabbour A, et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovascular imaging. 2016; 9:40–50.
Kalb B, Indik JH, Ott P, Martin DR.MRI of patients with implanted cardiac devices. J Magn Reson Imaging. 2018 Mar;47(3):595-603. doi: 10.1002
Weidman EK, Dean KE, Rivera W, Loftus ML, Stokes TW, Min RJ. MRI safety: a report of current practice and advancements in patient preparation and screening. Clin Imaging. 2015 Nov-Dec;39(6):935-7. doi: 10.1016.
Tsai LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. Radiographics. 2015 Oct;35(6):1722-37. doi: 10.1148
Sechtem U, Pﬂugfelder P, Higgins CB. Quantiﬁcation of cardiac function by conventional and cine magnetic resonance imaging. Cardiovasc Intervent Radiol 1987; 10: 365– 373
Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, de Roos A. Left ventricular measurements with cine and spin‐echo MRI imaging: a study of reproducibility with variance component analysis. Radiology 1993; 187: 261– 268.
Reichek N. Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q1991; 7: 255–274.
Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005; 7: 775– 782
Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006; 8: 417– 426.
Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady‐state free precession cardiovascular magnetic resonance. Eur Heart J 2006; 27: 2879–2888.
Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Rosenson RS, Schoﬁeld RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/ ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the american college of cardiology foundation task force on expert consensus documents. Circulation 2010;121:2462–2508.
Valsangiocomo Buechel ER, Mertens L. Imaging the right heart: the use of integrated multimodality imaging. Eur Heart J 2012; 33: 949–960
Grothues F, Moon J, Bellenger N, Smith G, Klein H, Pennell D. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218–223
Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. Eur Heart J 2010;31:794–805
Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep 2015;12:276–283
G. Pons-Llado, F. Carreras, X. Borras, J. Palmer, J. Llauger, A. Bayes de Luna Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol, 79 (1997), pp. 1651-1656.
J.C. Moon, N.G. Fisher, W.J. McKenna, D.J. Pennell Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart, 90 (2004), pp. 645-649.
R. Fattori, E. Biagini, M. Lorenzini, K. Buttazzi, L. Lovato, C. Rapezzi. Signiﬁcance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol, 105 (2010), pp. 1592-159.
Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular magnetic resonance characterization of left ventricular non-compaction provides independent prognostic information in patients with incident heart failure or suspected cardiomyopathy. J Cardiovasc Magn Reson 2014;16:64.
Choi Y, Kim SM, Lee SC, Chang SA, Jang SY, Choe YH. Quantiﬁcation of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non- compaction: evaluation of trabecular volume and reﬁned semi-quantitative criteria. J Cardiovasc Magn Reson 2016;18:24.
Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461–1474
Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H., Hasegawa T., Takahama H.,Amaki M., Asakura M., Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. EurJHeartFail 2013;15:166–175.
Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB. Myocardial T1 mapping and extracellular volume quantiﬁcation: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15:92
Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. Journal of cardiovascular magnetic resonance: ofﬁcial journal of the Society for Cardiovascular Magnetic Resonance. 2013;15:89.
Sobol, E. Horn, A. Dele-Michael et al. Assessment of unexplained cardiomyopathy: clinical utility of delayed enhancement cardiac magnetic resonance compared to endomyocardial biopsy. Journal of the American College of Cardiology. 2012 vol. 59, no. 13, p. E1553, 2012.
Theodoros D.KaramitsosMD, Christos A.Papanastasiou, Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis: The Best Way Forward. JACC Cardiovasc Imaging. 2019; 8: S1936-878X
Vogelsberg H., Mahrholdt H., Deluigi C.C. et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J. Am. Coll. Cardiol. 2008;51:1022–1030
Nam BD, Kim SM, Jung HN, et al. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping. Int J Cardiovasc Imaging. 2018;34(11):1769–77
Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015; 132:1570–9. [PubMed: 26362631]
Karur GR, Robison S, Iwanochko RM, et al. Use of myocardial T1 mapping at 3.0 T to differentiate Anderson-Fabry disease from hypertrophic cardiomyopathy. Radiology. 2018;288(2):398–406
Sado DM, White SK, Piechnik SK, et al. Identiﬁcation and assessment of Anderson- Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circulation Cardiovascular imaging. 2013; 6:392–8. [PubMed: 23564562]
Jianxiong Zhang, Yunxiao Li, Qiufen Xu, et al. Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A Meta-Analysis. Canadian Respiratory Journal Volume 2018, 10.
Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial ﬁbrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. European heart journal. 2012; 33:640–8
Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium enhancement cardiovascular magnetic resonance. Journal of cardiovascular magnetic resonance ofﬁcial journal of the Society for Cardiovascular Magnetic Resonance. 2011; 13:29
Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall ﬁbrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. Journal of the American College of Cardiology. 2012; 60:1659– 67
Daoulah A, Alsheikh-Ali AA, Al-Faiﬁ SM, Ocheltree SR, Haq E, Asrar FM, Fathey A, Haneef AA, Al Mousily F, O el-S, Lotﬁ A. Cardiac resynchronization therapy in patients with postero-lateral scar by cardiac magnetic resonance: A systematic review and meta-analysis. J Electrocardiol. 2015 Sep-Oct;48(5):783-90. doi: 10.1016
Acosta J, Fernández-Armenta J, Borràs R, Anguera I, Bisbal F, Martí-Almor J, Tolosana JM, Penela D, Andreu D, Soto-Iglesias D, Evertz R, Matiello M, Alonso C, Villuendas R, de Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra L, Planes X, Greiser A, Ekinci O, Lasalvia L, Mont L, Berruezo A. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI- CRT Study. JACC Cardiovasc Imaging. 2018 Apr;11(4):561-572. doi: 10.1016
Hoke U, Khidir MJ, van der Geest RJ, Schalij MJ, Bax JJ, Delgado V, Ajmone Marsan N. Relation of Myocardial Contrast-Enhanced T1 Mapping by Cardiac Magnetic Resonance to Left Ventricular Reverse Remodeling After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy.
Nguyen UC, Maﬁ-Rad M, Aben JP, Smulders MW, Engels EB, van Stipdonk AM, Luermans JG, Bekkers SC, Prinzen FW, Vernooy K. A novel approach for left ventricular lead placement in cardiac resynchronization therapy: Intraprocedural integration of coronary venous electroanatomic mapping with delayed enhancement cardiac magnetic resonance imaging. Heart Rhythm. 2017 Jan;14(1):110-119. doi: 10.1016.
Kockova R, Sedláček K, Wichterle D, Šikula V, Tintěra J, Jansová H, Pravečková A, Langová R, Krýže L, El-Husseini W, Segeťová M, Kautzner J. Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT). Int J Cardiol. 2018 Nov 1;270:325-330.
Iles L, Pﬂuger H, Lefkovits L, et al. Myocardial ﬁbrosis predicts appropriate device therapy in patients with implantable cardioverter-deﬁbrillators for primary prevention of sudden cardiac death. Journal of the American College of Cardiology. 2011; 57:821–8.
Disertori M, Rigoni M, Pace N, Casolo G, Masè M, Gonzini L, et al. Myocardial ﬁbrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction. A meta-analysis. J Am Coll Cardiol Img. 2016;9:1046-1055. Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA, et al.
Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan NA, Kaandorp TA, et alInfarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmias in patients with ischemic cardiomyopathy and implantable cardioverter-deﬁbrillator. Circ Cardiovasc Imaging. 2009;2:183-190.
Demirel F, Adiyaman A, Timmer JR, Dambrink JH, Kok M, Boeve WJ, et al. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy. Int J Cardiol. 2014;177:392-399.
Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur J Heart Fail. 2013;15:1019-1027.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325 (5):293–302.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090
Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril,or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349 (20):1893–1906.
Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002;40 (8):1414–1421
Dimopoulos K, Saukhe TV, Coats A et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol. 2004; 93 (2–3):105- 111
Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23):1429–1435.
Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995;273 (18):1450–1456.
Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., Rydén L., Thygesen K., Uretsky B.F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999 Dec 7;100(23):2312-8.
Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327 (10):669–677.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992;327(10):685–691.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efﬁcacy (AIRE) Study Investigators. Lancet. 1993;342 (8875):821–828.
Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338– 2345.
Pﬂugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B.Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double- blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63. doi: 10.1016/0735-1097(93)90578-o.
Widimský J, Kremer HJ, Jerie P, Uhlír O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995; 49(1-2):95-102. doi: 10.1007/BF00192366.
Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efﬁcacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995 Dec;16(12):1892-9. doi: 10.1093/oxfordjournals.eurheartj.a060844.
McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993–1004.
Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334 (21):1349–1355.
Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91 (2):169–174.
The Cardiac Insufﬁciency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353 (9146):9–13.
Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357:1385- 1390.
Jondeau G., Neuder Y., Eicher J.C. et al. B-CONVINCED: Betablocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30 (18):2186–2192
Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.
Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551
McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand I.S., Bělohlávek J., Böhm M., Chiang C.-E., Chopra V.K., de Boer R.A., Desai A.S., Diez M., Drozdz J., Dukát A., Ge J., Howlett J.G., Katova T., Kitakaze M., Ljungman C.E.A., Merkely B., Nicolau J.C., O’Meara E., Petrie M.C., Vinh P.N, Schou M., Tereshchenko S., Verma S., Held C., DeMets D.L., Docherty K.F., Jhund P.S., Bengtsson O., Sjöstrand M., Langkilde A.-M. Dapagliﬂozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019 DOI: 10.1056/NEJMoa1911303
Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A.. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol 2002;82:149–158.
Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure.Cochrane Database Syst Rev 2012;2:CD003838.
Dormans T.P., van Meyel J.J., Gerlag P.G. et al. Diuretic efﬁcacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28 (2):376–382
Vargo D.L., Kramer W.G., Black P.K. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther.1995;57 (6):601–609.
Patterson J.H., Adams K.F. Jr, Applefeld M.M. et al. for the Torаsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14 (5):514–521
Brater D. Torasemid: pharmacokinetic and clinical efﬁcacy. Eur J Heart Fail. 2001;3 (Suppl G): 19–24.
Cosin J., Diez J., Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513
Fortuno A., Muniz P., Ravassa S. et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension.1999;34 (1):138–143.
Yamato M., Sasaki T., Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390
Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM–Alternative trial. Lancet. 2003;362 (9386):772– 776.
Cohn J.N., Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med.2001; 345 (23):1667–1675
McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin- convertingenzyme inhibitors: the CHARM–Added trial. Lancet. 2003; 362 (9386):767–771.
Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil J-C, Swedberg K, Tavazzi L. Heart rate at baseline inﬂuences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102:11–22
Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744):875–885
Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an inﬂuence of beta-blocker dose?: ﬁndings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012;59:1938– 1945
Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29
Digoxin"s effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group. Cleve Clin J Med. 1997 May; 64 (5):234-7.
Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack of evidence of increased mortality among patients with atrial ﬁbrillation taking digoxin: ﬁndings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34 (20):1489–1497
Jorge E., Baptista R., Martins H. et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013;32 (4):303–310
Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral digoxin in high-risk heart failure patients: a pre-speciﬁed subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15 (5):551–559
Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–878.
Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46 (3):497–504.
Malik A, Masson R, Singh S, Wu W, Packer M, Pitt B, Waagstein F, Morgan C, Allman R, Fonarow G, Ahmed A. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology Aug 2019, 74 (5) 617-627; DOI: 10.1016/j.jacc.2019.05.064
The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1223―30.
Lucas M, Kimmig M, Karalis G. Do omega-3 polyunsaturated fatty acids prevent cardiovascular disease? A review of the randomized clinical trials. Lipid Insights 2013;6:13– 20
Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314 (24):1547–1552.
Taylor A.L., Ziesche S., Yancy C. et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351 (20):2049–2057.
Carson P., Ziesche S., Johnson G., Cohn J.N., for the Vasodilator –Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5 (3):178–187
Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 2005;7 (6):1059–1069.
Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI–HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 (9645):1231–1239.
Homma S., Thompson J.L., Pullicino P.M. et al, WARCEF Investigators.Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366 (20):1859– 1869
Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848.
Sulaica EM, Macaulay TE, Helbing RR, Abo-Aly M, Abdel-Latif A45, Wanat MA. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev. 2019 Jun 29. doi: 10.1007/s10741-019-09818-w. [Epub ahead of print
Gheorghiade M., Böhm M., Greene S.J., Fonarow G.C., Lewis E.F., Zannad F.,Solomon S.D., Baschiera F., Botha J., Hua T.A., Gimpelewicz C.R., Jaumont X., Lesogor A., Maggioni A.P.; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20;309(11):1125-35.
Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides M., Richard A., Xiang Z., Brunel P., Pfeffer M.A.; ALTITUDEInvestigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.N Engl J Med. 2012 Dec 6;367(23):2204-13. 131
Komajda M., McMurray J.J., Beck-Nielsen H., Gomis R., Hanefeld M., Pocock S.J.,Curtis P.S., Jones N.P., Home P.D. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824–831
Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115–128
Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-Benedetti M., Yates J.,Tan M., Spanheimer R., Standl E., Dormandy J.A. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773–2778.139-141
Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52–60
Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator – Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856–863
Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials update: OPTIME–CHF, PRAISE-2, ALL–HAT. Eur J Heart Fail. 2000;2(2):209–212.
Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996; 335 (15):1107–1114
Huerta C., Varas-Lorenzo C., Castellsague J., Garcia Rodriguez L.A. Non-steroidal anti-inﬂammatory drugs and risk of ﬁrst hospital admission for heart failure in the general population. Heart 2006;92:1610–1615
Preliminary report: effect of encainide and ﬂecainide on mortality in a randomized trial of arrhythmia suppressionafter myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321(6):406-12
Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, ﬂecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2016) 37, 2129–2200 doi:10.1093/eurheartj/ehw128
Cleland JGF, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, Chattopadhyay S, Norell MS, Pennell DJ, Senior R. The heart failure revascularization trial (HEART). Eur J Heart Fail 2011;13:227–233
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau J-L, STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607–1616
Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Borges-Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013;61:1860–1870
Carson P, Wertheimer J, Miller A, O’Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail 2013;1: 400–408
Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194–2199
Poole – Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7– 13.
Desai AS, McMurray JJ, Packer M. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 7;36(30):1990-7. doi: 10.1093/eurheartj/ehv186.
Wyse D., Friedman P.L., Epstein A.E. A comparison of antiarrhythmic-drug therapy with implantable deﬁbrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Deﬁbrillators (AVID) Investigators. N Engl J Med 1997;337:1576–1583
Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H., Zipes D.P., Greene H.L., Boczor S., Domanski M., Follmann D., Gent M., Roberts R.S. Meta-analysis of the implantable cardioverter deﬁbrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Deﬁbrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Deﬁbrillator Study. Eur Heart J 2000;21:2071–2078
Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon R.S., Mitchell L.B.,Green M.S., Klein G.J., O’Brien B. Canadian implantable deﬁbrillator study (CIDS): a randomized trial of the implantable cardioverter deﬁbrillator against amiodarone.Circulation 2000;101:1297–1302
Kuck K.H., Cappato R., Siebels J., Ru¨ppel R. Randomized comparison of antiarrhythmic drug therapy with implantable deﬁbrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102: 748–754
Oseroff O., Retyk E., Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-deﬁbrillator trials: antiarrhythmics versus implantable deﬁbrillators (AVID), Canadian Implantable Deﬁbrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004;19:26–30
Al-Khatib SM, Sanders GD, Mark DB et al. Implantable cardioverter deﬁbrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J. 2005 Jun;149(6):1020-34. DOI: 10.1016/j.ahj.2005.02.005.
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Kober L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41–51. doi: 10.1056/NEJMoa1609758.
Lafuente-Lafuente C, Valembois L, Bergmann J-F, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial ﬁbrillation. Cochrane Database Syst Rev 2012;5:CD005049
Increased mortality after dronedarone therapy for severe heart failure, ﬂecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J 1992; 13:1251–1258
Kober L, Torp-Pedersen C, McMurray JJV, Gøtzsche O, Le´vy S, Crijns H, Amlie J,,Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678–2687
Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009 Jan 27;53(4):355-60. doi: 10.1016/j.jacc.2008.09.043
Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip JH. Amiodarone or an implantable cardioverter– deﬁbrillator for congestive heart failure. N Engl J Med2005;352:225–237
Torp-Pedersen C., Metra M., Spark P., Lukas M.A., Moullet C., Scherhag A., Komajda M., Cleland JGF, Remme W., Di Lenarda A., Swedberg K., Poole-Wilson P.A. The safety of amiodarone in patients with heart failure. J Card Fail 2007;13:340–345
Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77–82
Deyell MW, Park KM, Han Y, Frankel DS, Dixit S, Cooper JM, Hutchinson MD, Lin D, Garcia F, Bala R, Riley MP, Gerstenfeld E, Callans DJ, Marchlinski FE. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012;9:1465–1472
Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, ArmstrongW, Good E, Chugh A, Jongnarangsin K, Pelosi F Jr., Crawford T, Ebinger M, Oral H, Morady F, Bogun F. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865–869
Ban JE, Park HC, Park JS, Nagamoto Y, Choi JI, Lim HE, Park SW, Kim YH. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace 2013;15:735–741
Chatterjee S., Ghosh J., Lichstein E., Aikat S., Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial ﬁbrillation or heart failure. Am J Cardiol 2012;110:607–613
Atti V, Vuddanda V, Turagam MK, Vemula P, Shah Z, Nagam H, Yandrapalli S, Jazayeri MA, Koerber S, Gonzalez JV, Natale A, Di Biase L, Lakkireddy DR. Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018 Nov;53(2):207-215. doi: 10.1007/s10840-018-0376-5. Epub 2018 Apr 21
Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS, Dixit S, Epstein AE, Callans DJ, Marchlinski FE. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-deﬁbrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016 Jul;13(7):1552-9. doi: 10.1016/j.hrthm.2016.03.004. Epub 2016 Mar 4. Review
Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Deﬁbrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial.JAMA. 2006; 295:165–171. doi: 10.1001/jama.295.2.165.
Dinov B, Fiedler L, Schonbauer R, Bollmann A, Rolf S, Piorkowski C, Hindricks G, Arya A. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014; 129:728–736
Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993;4:253–262.
Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, Akhtar M. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:256–270.
Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, Juta R, Tsang B, Joza J, Nascimento T, Pegoraro V, Khaykin Y, Verma A. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace. 2015;17:461–467.
Tchou P, Jazayeri M, Denker S, Dongas J, Caceres J, Akhtar M. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988;78: 246–257.
Tzou WS, Tung R, Frankel DS, Vaseghi M, Bunch TJ, Di Biase L, Tholakanahalli VN, Lakkireddy D, Dickfeld T, Saliaris A, Weiss JP, Mathuria N, Tedrow U, Afzal MR, Vergara P, Nagashima K, Patel M, Nakahara S, Vakil K, Burkhardt JD, Tseng CH, Natale A, Shivkumar K, Callans DJ, Stevenson WG, Della Bella P, Marchlinski FE, Sauer WH.Ventricular Tachycardia Ablation in Severe Heart Failure: An International Ventricular TachycardiaAblation Center Collaboration Analysis Circ Arrhythm Electrophysiol. 2017 Jan;10(1)
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Reﬁning clinical risk stratiﬁcation for predicting stroke and thromboembolism in atrial ﬁbrillation using a novel risk factor- based approach: the euro heart survey on atrial ﬁbrillation. Chest 2010; 137:263–272
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratiﬁcation schemes for predicting stroke and thromboembolism in patients with atrial ﬁbrillation: nationwide cohort study. BMJ 2011;342:d124.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratiﬁcation schemes for ischaemic stroke and bleeding in 182 678 patients with atrial ﬁbrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial ﬁbrillation. Ann Intern Med 2007; 146:857– 867
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD,Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2009;361:1139–1151
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J,Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2011;365:981–992
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial ﬁbrillation. N Engl J Med 2011;365:883–891.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2013;369:2093–2104
Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial ﬁbrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17:1192–1200
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efﬁcacy and safety of new oral anticoagulants with warfarin in patients with atrial ﬁbrillation: a meta-analysis of randomised trials. Lancet 2014;383: 955–962
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators. Efﬁcacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial ﬁbrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–983
Pedersen O.D., Bagger H., Køber L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial ﬁbrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376–380
Ducharme A., Swedberg K., Pfeffer M.A., CohenSolal A., Granger C.B., Maggioni A.P., Michelson E.L., McMurrayJJ V., Olsson L., Rouleau J.L., Young J.B., Olofsson B., Puu M., Yusuf S.. Prevention of atrial ﬁbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86–92.
McMurray J., Køber L., Robertson M., Dargie H., Colucci W., Lopez-Sendon J., Remme W., Sharpe D.N., Ford I.Antiarrhythmic effect of carvedilol after acute myocardial infarction. J Am Coll Cardiol 2005;45:525–530.
Swedberg K., Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Shi H., Vincent J., Pitt B. Eplerenone and atrial ﬁbrillation in mild systolic heart failure. J Am Coll Cardiol 2012;59:1598–1603.
Han M., Zhang Y., Sun S., Wang Z., Wang J., Xie X., Gao M., Yin X., Hou Y. Renin– angiotensin system inhibitors prevent the recurrence of atrial ﬁbrillation. J Cardiovasc Pharmacol 2013;62:405–415.
Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luckett C.R., Henry W.L. Amiodarone for maintenance of sinus rhythm after conversion of atrial ﬁbrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572–575
Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial ﬁbrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574–2579
Shelton R.J., Clark A.L., Goode K., Rigby A.S., Houghton T., Kaye G.C., Cleland JGF. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial ﬁbrillation and heart failure: (CAFE-II Study).Heart 2009;95:924–930.
Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral amiodarone increases the efﬁcacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial ﬁbrillation. Eur Heart J 2000;21:66–73
Hofmann R., Steinwender C., Kammler J., Kypta A., Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial ﬁbrillation and a rapid ventricular rate. Int J Cardiol 2006;110:27–32
Hofmann R., Wimmer G., Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial ﬁbrillation accompanied by severe congestive heart failure. Heart 2000;84:635
Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JGP, Veeger NJGM, Van Gelder IC. Rate control versus rhythm control for patients with persistent atrial ﬁbrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005;149:1106–1111.
Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP, Crijns HJGM. A comparison of rate control and rhythm control in patients with recurrent persistent atrial ﬁbrillation. N Engl J Med 2002;347:1834–1840.
Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJGM, RACE and AFFIRM Investigators. Does intensity of rate-control inﬂuence outcome in atrial ﬁbrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935–942
Li S-J, Sartipy U, Lund LH, Dahlstro¨m U, Adiels M, Petzold M, Fu M. Prognostic signiﬁcance of resting heart rate and use of b-blockers in atrial ﬁbrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: ﬁndings from the Swedish Heart Failure Registry. Circ Heart Fail 2015;8:871–879
Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate control In. J Fam Practice 2000; 49:47–59.
Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L., Cleland J.G.F., Lip G.Y.H., Coats A.J.S., Andersson B., Kirchhof P., vonLueder T.G., Wedel H., Rosano G., Shibata M.C., Rigby A., Flather M.D. Efﬁcacy of β blockers in patients with heart failure plus atrial ﬁbrillation: an individual-patient data meta-analysis. Lancet2014;384:2235–2243
Ziff OJ, Lane DA, Samra M, Grifﬁth M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D. Safety and efﬁcacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
Sethi NJ, Nielsen EE, Saﬁ S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial ﬁbrillation and atrial ﬂutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018 Mar 8;13(3):e0193924. doi: 10.1371/journal.pone.0193924. eCollection 2018
Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., Pires L.A. PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160–1165
Rationale and design of a study assessing treatment strategies of atrial ﬁbrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.Am Heart J. 2002 Oct;144 (4):597-607
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378:417-427
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693
Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL; CABANA Investigators. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019.
Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, Dai J, Xu X, Mao W. Catheter ablation versus medical therapy for patients with persistent atrial ﬁbrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol. 2018;52:9-18.
Cleland JG, Keshavarzi F, Pellicori P, Dicken B. Case selection for cardiac resynchronization in atrial ﬁbrillation. Heart Fail Clin. 2013;9:461-74.
Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, Quartieri F, Calò L, Ungar A, Mont L; APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial ﬁbrillation and narrow QRS. Eur Heart J. 2018;39:3999-4008
Bohm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efﬁcacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM- HF. Eur Heart J. 2017,38 (15):1132-43. https://doi.org/10.1093/eur-heartj/ehw570.
Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658.
MERIT-HF Study Group. Effects of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001–2007.
Schmieder RE, Rockstroh JK. Efﬁcacy and tolerance of low-dose loop diuretics in hypertension. Cardiology. 1994;84 Suppl 2:36-42.
Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efﬁcacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung. 1988 Jan;38(1A):190-3.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018 Aug;36(8):1637-1647. doi: 10.1097/HJH.0000000000001777
Packer, M., Carson, P., Elkayam, U., Konstam, M. A., Moe, G., O’Connor, C., DeMets, D. L. (2013). Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure, 1(4), 308–314. doi:10.1016/j.jchf.2013.04.004
Physicians Desk Reference. 47th ed. Montvale. NJ: Medical Economics Company, 1993: 2250.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–667
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. ALLHAT Collaborative Research Group. JAMA 2000;283: 1967–1975.
Dorszewski A, Go¨hmann E, Dorsz´ewski B, Werner GS, Kreuzer H, Figulla HR. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneﬁcial: results of a placebo-controlled, double-blind study. J Card Fail 1997;3:91–96.
Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed) 1985;290:1861–1865
Kjekshus J, Apetrei E, Barrios V, Bo¨hm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Ja´nosi A, Kamensky´ G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–2261.
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807–816.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337–2345
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.
Vitale C, Spoletini I, MalorniW, Perrone-Filardi P, Volterrani M, Rosano GMC. Efﬁcacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina—the VASCO-angina study. Int J Cardiol 2013;168:1078–1081.
Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GMC. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25: 1814–1821.
Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart 2011;97:278–286
Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5:476–490.
Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta- analysis. Lancet 2009;373:911–918
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel et al. Empagliﬂozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (22):2117– 28. DOI:10.1056 / NEJMoa1504720.
Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliﬂozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology. 2016;15 (1). DOI:10.1186 / s12933‑016‑0356‑y.
Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliﬂozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation. 2018;138:458-468
Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation. 2005;111 (5):583–90. DOI:10.1161 / 01. CIR. 0000154542.13412. B1.
Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345_2351.
MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, Petrie MC, McMurray JJ V, Petrie JR, McAlister FA. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010;33:1213–1218.
Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J-P, Kassai B, Moreau A, Gueyfﬁer F, Cornu C. Reappraisal of metformin efﬁcacy in the treatment of type 2 diabetes: a meta- analysis of randomised controlled trials. PLoS Med 2012;9:e1001204
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69- 79
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-1239.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstﬁeld JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-2257.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsboll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med;doi:10.1056/NEJMoa1901118. Published online ahead of print 11 June 2019.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstﬁeld J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130.
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, Nilsson B, Moller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, doubleblind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69-77.
Margulies KB, Hernandez AF, Redﬁeld MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-508
Hawkins NM, Macdonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial, Eur J Heart Fail , 2009, vol. 11 (pg. 684-690)
Lainscak M, Podbregar M, Kovacic D, Rozman J, von HS. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial, Respir Med , 2011, vol. 105 Suppl. 1(pg. S44-S49)
Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial, J Am Coll Cardiol , 2010, vol. 55 (pg. 1780-1787)
Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease, Cochrane Database Syst Rev , 2005pg. CD003566
Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R. , investigators C-E, Project Multicentre Trials in the Competence Network Heart F. Titration to target dose of bisoprolol vs. Carvedilol in elderly patients with heart failure: The CIBIS-ELD trial, Eur J Heart Fail , 2011, vol. 13 (pg. 670-680)].
Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M et al. Clinical proﬁles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efﬁcacy and safety analysis of SHIFT study. International Journal of Cardiology. 2013;170 (2):182–8. DOI:10.1016 / j. ijcard. 2013.10.068
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJV, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210–1219
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneﬁcial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deﬁciency. Eur Heart J 2015;36:657–668.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deﬁciency. N Engl J Med 2009;361:2436–2448
Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–641.
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206–14
Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35 (1):503–11. DOI:10.1146 / annurev.me. 35.020184.002443.
Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6 (6):469–80. PMID:10213794.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5‑HT1A receptor. Eur J Pharmacol. 2002;441 (3):137–40. PMID:12063084
Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C, Heuschmann PU, и др. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients’ mood.. Eur J Heart Fail. 2014;16(10):1133–41. DOI:10.1002/ejhf.150
Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials [Интернет]. 2011 [цитируется по 1 февраль 2018 г.];12(1). DOI:10.1186/1745-6215-12-194
de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA, и др. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study. Heart. 2007;93(7):819–25. DOI:10.1136/hrt.2006.095810
Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D, и др. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review.. Eur J Heart Fail. 2014;16(7):749–57. DOI:10.1002/ejhf.101
Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы для пациентов с сердечной недостаточностью. Есть ли ШАНС повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ исследования ШАНС (Школа и Амбулаторное Наблюдение больных Сердечной недостаточностью). Журнал Сердечная Недостаточность. 2016;17(6):433–42. DOI:10.18087/rhfj.2016.6.2281
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al. Safety and Efﬁcacy of Sertraline for Depression in Patients With Heart Failure. Journal of the American College of Cardiology. 2010;56 (9):692–9. DOI:10.1016 / j. jacc. 2010.03.068
Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315 (24):2683. DOI:10.1001 / jama. 2016.7635
Heiat A., Gross C.P., Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med. 2002, (162):1682-1688
Seo WW, Park JJ, Park HA, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open. 2020; 10(2):e030514. Published 2020 Feb 6. doi:10.1136/bmjopen-2019-030514.
Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta- blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double- blind randomized trials. Eur Heart J 2018;39:26-35
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Aug; 20:1230-1239.
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O"Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Inﬂuence of ejection fraction on outcomes and efﬁcacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016; 37: 455-62.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redﬁeld MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.PMID: 31475794
Ahmed A1, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 1; 114(5):397- 403. DOI: 10.1161/CIRCULATIONAHA.106.628347
Azizova A.G., Ovchinnikov A.G., Blankova Z.N., Ageev F.T. In patients with elevated LV ﬁlling pressure loop diuretics improve severity of heart failure and diastolic dysfunction, but torasemide does it somewhat better than furosemide. Eur J Heart Fail 2011;10 (Suppl 2):S186.
Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):935-44. doi: 10.1161/CIRCHEARTFAILURE.113.001229.
Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215–225.
Mulder BA, van Veldhuisen DJ, Crijns HJGM, Bo¨hm M, Cohen-Solal A, Babalis D, Roughton M, Flather MD, Coats AJS, Van Gelder IC. Effect of nebivolol on outcome in elderly patients with heart failure and atrial ﬁbrillation: insights from SENIORS. Eur J Heart Fail 2012;14:1171–1178.
van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJS, Poole-Wilson PA, Flather MD. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009;53:2150–2158.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ V, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781
Hernandez AF, Hammill BG, O"Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: ﬁndings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009 Jan 13;53(2):184-92
Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2018 Jun 28;6:CD012721
402 Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019;381:1609-1620. doi: 10.1056/NEJMoa1908655.
Fadi Hage , Ali Hage , Haissam Haddad , Bob Kiaii. Update on revascularization in patients with heart failure and coronary artery disease. Curr Opin Cardiol. 2018 Mar;33(2):232-236. doi: 10.1097/HCO.0000000000000483
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511–1520.
Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver TM, Djokovic LT, Wang N, Velazquez EJ, Sopko G, Kron IL, DiMaio JM, Michler RE, Lee KL, Yii M, Leng CY, Zembala M, Rouleau JL, Daly RC, Al-Khalidi HR. Inﬂuence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricu- lar dysfunction: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation 2015;132:720–730.
Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344: 563–570
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in patients with multivessel coronary artery disease and severe left ventricular sys- tolic dysfunction: Everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation 2016;133:2132–2140
Wolff G, Dimitroulis D, Andreotti F, Kolodziejczak M, Jung C, Scicchitano P, Devito F, Zito A, Occhipinti M, Castiglioni B, Calveri G, Maisano F, Ciccone MM, De Servi S, Navarese EP. Survival beneﬁts of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: A meta-analysis. Circ Heart Fail 2017;10:e003255
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing andimpact of revascularization on prognosis in patients with coronary artery diseaseand left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39(7):1151–1158
Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, Holly TA, Oh JK, Dagenais F, Milano C, Wrobel K, Pirk J, Ali IS, Jones RH, Velazquez EJ, Lee KL, Di Donato M, STICH Trial Investigators. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting. with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146:1139–1145.e6
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360:1705–1717
Dor V, Civaia F, Alexandrescu C, Sabatier M, Montiglio F. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical. Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2011;141:905–916, 916 e1–e4
Oh JK, Velazquez EJ, Menicanti L, Pohost GM, Bonow RO, Lin G, Hellkamp AS, Ferrazzi P, Wos S, Rao V, Berman D, Bochenek A, Cherniavsky A, Rogowski J, Rouleau JL, Lee KL, STICH Investigators. Inﬂuence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J 2013;34:39–47.]
Cazeau S.,Leclercq C.,Lavergne T.,Walker S.,Varma C.,Linde C.,Garrigue S., Kappenberger L.,Haywood G.A.,Santini M.,Bailleul C.,Mabo P.,Lazarus A.,Ritter P.,Levy T.,McKenna W.,Daubert J-C. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med2001;344:873–880.
Сleland J.,Daubert J.,Erdmann E.,Freemantle N.,Gras D.,Kappenberger L.,Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549.
Cleland JGF, Daubert J-C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928–1932.
Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert J- CC. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization–Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012;14:628–634.
Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W., Feldman A.M. Cardiac-resynchronization therapy with or without an implantable deﬁbrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.
Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B., Claude Daubert J., Sherfesee L.,Wells G.A., Tang ASL. An individual patient meta-analysis of ﬁve randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34:3547–3556.
Tang ASL, Wells G.A., Talajic M., Arnold M.O., Sheldon R., Connolly S., Hohnloser S.H., Nichol G., Birnie D.H., Sapp J.L., Yee R., Healey J.S., Rouleau J.L.Cardiac- resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385– 2395.
Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert J.P., Estes NAM, Foster E., Greenberg H., Higgins S.L., Pfeffer M.A., Solomon S.D., Wilber D., ZarebaW. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–1338.
Goldenberg I., Kutyifa V., Klein H.U., Cannom D.S., Brown M.W., Dan A., Daubert J.P., Estes NAM., Foster E., Greenberg H., Kautzner J., Klempfner R., Kuniss M., Merkely B., Pfeffer M.A., Quesada A., Viskin S., McNitt S., Polonsky B., Ghanem A., Solomon S.D., Wilber D., ZarebaW., Moss A.J. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694–1701.
Linde C., Abraham W.T., Gold M.R, St John Sutton M., Ghio S., Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834–1843.
Daubert C., Gold MR., Abraham W.T., Ghio S., Hassager C., Goode G., Szili-To¨ro¨k T., Linde C., REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE trial. J Am Coll Cardiol 2009;54:1837–1846.
Linde C., Gold M.R., Abraham W.T., St John Sutton M., Ghio S., Cerkvenik J., Daubert C.. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013;34:2592–2599
Woods B., Hawkins N., Mealing S., Sutton A., Abraham W.T., Beshai J.F., Klein H., Sculpher M., Plummer C.J., Cowie M.R. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101:1800–1806
Curtis A.B.,Worley S.J., Adamson P.B., Chung E.S., Niazi I., Sherfesee L., Shinn T, St John Sutton M.. Biventricular pacing for atrioventricular block and systolic dysfunction.N Engl J Med 2013;368:1585–1593.
Brignole M., Botto G., Mont L., Iacopino S., De Marchi G., Oddone D., Luzi M., Tolosana J.M., Navazio A., Menozzi C. Cardiac resynchronization therapy in patientsundergoing atrioventricular junction ablation for permanent atrial ﬁbrillation: a randomized trial. Eur Heart J 2011;32:2420–2429.
Leclercq C.,Walker S., Linde C., Clementy J., Marshall A.J., Ritter P., Djiane P., Mabo P., Levy T., Gadler F., Bailleul C., Daubert J-C. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial ﬁbrillation. Eur Heart J 2002;23:1780–1787.
Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial ﬁbrillation: a meta-analysis. Europace 2012;14:1490–1497
MacDonald M.R., Connelly D.T., Hawkins N.M., Steedman T., Payne J., Shaw M.,Denvir M., Bhagra S., Small S., Martin W., McMurray J.J., Petrie M.C. Radiofrequency ablation for persistent atrial ﬁbrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011;97:740–747.
Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P., Rahman-Haley S.L.,McDonagh T.A., Underwood S.R., Markides V., Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial ﬁbrillation in heart failure. J Am Coll Cardiol 2013;61:1894–1903.
Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh J.P. Cardiac resynchronization in patients with atrial ﬁbrillation: a meta-analysis of prospective cohortstudies. J Am Coll Cardiol 2008;52:1239–1246.
Gasparini M., Leclercq C., Lunati M., Landolina M., Auricchio A., Santini M., Boriani G., Lamp B., Proclemer A., Curnis A., Klersy C., Leyva F. Cardiac resynchronization therapy in patients with atrial ﬁbrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013;1:500–507
Gage R.M., Burns K.V., Bank A.J. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014;16:1199–1205.
Funck RC, Mueller H-H, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg M, Wuensch D, Blanc J-J. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace 2014; 16:354–362.
Ruschitzka F., AbrahamW.T., Singh J.P., Bax J.J., Borer J.S., Brugada J., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard P., Holzmeister J. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395–1405
Steffel J., Robertson M., Singh J.P., Abraham W.T., Bax J.J., Borer J.S., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard P., Holzmeister J., Brugada J., Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015;36:1983–1989
Zusterzeel R., Selzman K.A., Sanders W., Can˜os D.A., O’Callaghan K.M., Carpenter J.L., Pin˜a I.L., Strauss D.G. Cardiac resynchronization therapy in women:US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014;174:1340–1348
Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W.,Andrews M.L.Prophylactic implantation of a deﬁbrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883
Desai A.S., Fang J.C., Maisel W.H., Baughman K.L. Implantable deﬁbrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA2004;292:2874–2879;
Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter- deﬁbrillators. N Engl J Med 2005;353:1471–1480
Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., Connolly S.J.Prophylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial infarction. N Engl J Med2004;351:2481–2488
TeinbeckG., AndresenD., SeidlK., BrachmannJ., HoffmannE., WojciechowskiD., Kornacewicz-JachZ., SredniawaB., LupkovicsG., HofgärtnerF., LubinskiA., RosenqvistM., HabetsA., WegscheiderK., SengesJ. Deﬁbrillatorimplantationearlyaftermyocardialinfarction. N Engl J Med 2009;361:1427–1436
Steinberg B.A., AlKhatib S.M., Edwards R., Han J., Bardy G.H., Bigger J.T., Buxton A.E., Moss A.J., Lee K.L.,Steinman R., Dorian P., Hallstrom A., Cappato R., Kadish A.H., Kudenchuk P.J., Mark D.B., Inoue LYT, Sanders G.D.Outcomes of implantable cardioverter-deﬁbrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014;2:623–629
Raphael C.E., Finegold J.A., Barron A.J., Whinnett Z.I., Mayet J., Linde C., Cleland JGF., Levy W.C., Francis D.P. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter deﬁbrillator therapy: who beneﬁts the most? Eur Heart J 2015;36:1676–1688.;
Miller RJH., Howlett J.G., Exner D.V., Campbell P.M., Grant ADM.,Wilton S.B. Baseline functional class and therapeutic efﬁcacy of common heart failure interventions: a systematic review and meta-analysis. Can J Cardiol2015;31:792–799; Hess P.L., AlKhatib S.M., Han J.Y., Edwards R., Bardy G.H., Bigger J.T., Buxton A., Cappato R., Dorian P.,Hallstrom A., Kadish A.H., Kudenchuk P.J., Lee K.L., Mark D.B., Moss A.J., Steinman R., Inoue LYT, Sanders G. Survival beneﬁt of the primary prevention implantable cardioverter-deﬁbrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015;8:179–186
Merchant F.M., Jones P., Wehrenberg S., Lloyd M.S., Saxon L.A. Incidence of deﬁbrillator shocks after elective generator exchange following uneventful ﬁrst battery life. J Am Heart Assoc 2014;3:e001289
Yap S-C., Schaer B.A., Bhagwandien R.E., Kuhne M., Dabiri Abkenari L., Osswald S., Szili-Torok T., Sticherling C.,Theuns D.A. Evaluation of the need of elective implantable cardioverter-deﬁbrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart 2014;100:1188–1192
Kini V., Souﬁ M.K., Deo R., Epstein A.E., Bala R., Riley M., Groeneveld P.W., Shalaby A., Dixit S. Appropriateness of primary prevention implantable cardioverter-deﬁbrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol 2014;63:2388– 2394.
Erkapic D., Sperzel J., Stiller S., Meltendorf U., Mermi J., Wegscheider K., Hügl B. Long-term beneﬁt of implantable cardioverter/deﬁbrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial—a prospective multicentre study. Eur Heart J 2013;34:130–137.
Alsheikh-Ali A.A., Homer M., Maddukuri P.V., Kalsmith B., Estes NAM, Link M.S. Time-dependence of appropriate implantable deﬁbrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol2008;19:784–789
León Salas B, Trujillo-Martín MM, García García J, Ramallo Fariña Y, García Quintana A, Quirós López R, Serrano-Aguilar P. Pacing Clin Electrophysiol. 2019 Aug 9. doi: 10.1111/pace.13774 Subcutaneous implantable cardioverter-deﬁbrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis
Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuß G. A Randomized Controlled Trial to Evaluate the Safety and Efﬁcacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6:874-883;
Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efﬁcacy of cardiaccontractility modulation in advanced heart failure. J Card Fail. 2011 Sep;17(9):710-7. doi: 10.1016/j.cardfail.2011.05.006. Epub 2011 Jun 22.
Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Abraham WT. A randomized controlled trial evaluating the safety and efﬁcacy of cardiac contractilitymodulation in advanced heart failure. Am Heart J. 2011 Feb;161(2):329-337.e1-2. doi: 10.1016/j.ahj.2010.10.025.
Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, Misier AR, Curnis A, Böcker D, Remppis A, Kautzner J, Stühlinger M, Leclerq C, Táborsky M, Frigerio M, Parides M, Burkhoff D, Hindricks G. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008 Apr;29(8):1019-28. doi: 10.1093/eurheartj/ehn020. Epub 2008 Feb 12
Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate 1000 ip left ventricular assist device. Ann Thorac Surg. 1992;53:1080-1090.
Gustafsson F, Morshuis M, Zimpfer D et al, on behalf of the ELEVATE investigators. Clinical outcomes with HeartMate 3 as a treatment for advanced hF: First data from the European ELEVATE Registry. Presented at the 37th ISHLT, San Diego, 2017.
Jorde UP, Kushwaha SS, Tootles AJ, et al. Results of the destination therapy post-food and drug dministration approval study with a continuous ﬂow left ventricular assist device: a prospective study using the INTERMACS ‡ registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-1757.
Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, Acker MA, Goldstein DL, Silvestry SC, Milano CA, Timothy Baldwin J, Pinney S, Eduardo Rame J, Miller MA. Interagency registry for mechanically assisted circulatory support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014; 33:12-22
Mehra MR, Salerno C, Cleveland JC, et al. Health Care Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: A Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure. Circulation. 2018 May 27. pii: CIRCULATIONAHA.118.035722
Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019 March 17.
Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto J. Multicenter study evaluating a fully magnetically levitated left ventricular assist system for the treatment of advanced heart failure. J Am Coll Cardiol. 2015.
Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Steven- son LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The rematch trial: Rationale, design, and end points. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg. 1999;67:723-730.
Schmitto JD, Hanke JS, Rojas SV, Avsar M, Haverich A. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant. 2015;34:858-860.
Starling RC, Estep JD, Horstmanshof DA, Milano CA, et al; ROADMAP Study Investigators (2017). Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. JACC Heart Fail,2017; 5:518-527.
O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S, Ellis S.J., LeiferE.S.,Kraus W.E., Kitzman D.W., Blumenthal J.A., Rendall D.S., Miller N.H., FlegJ.L.,Schulman K.A., McKelvie R.S., Zannad F., Pin˜a I.L., HF-ACTION Investigators. Efﬁcacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439–1450.
Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;4:CD003331
Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen H-D, Duvinage A, Hoischen N, Von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B, Edelmann F. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 2015;22:582–593.
IsmailH, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail 2013;1:514–522. 289
Piepoli MF , Conraads V, Corrà U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid J-P, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347–357
Wang MH, Yeh ML. Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trials. World J Clin Cases 2019; 7(18): 2760-2775
Adamopoulos S, Schmid J-P, Dendale P, Poerschke D, Hansen D, Dritsas A, и др. Combined aerobic/inspiratory muscle training vs. aerobic training in patients with chronic heart failure: The Vent-HeFT trial: a European prospective multicentre randomized trial. European Journal of Heart Failure. 2014;16(5):574–82. DOI:10.1002/ejhf.70
Feltner C, Jones CD, Cene´ CW, Zheng Z-J, Sueta CA, Coker-Schwimmer EJLL, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014;160:774–784
McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810–819
Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004;291:1358–1367.
Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneﬁcial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999;159:257–261.
Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K, Ulriksen H, Hildebrandt PR. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J 2013;34:432–442.
Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW, de Jong R, Linssen G, Lok DJA, Berge M, van Veldhuisen DJ. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 2014;16:1241–1248
Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the ﬁrst 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209–216.
Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17: 501–509;
Nieminen M., Brutsaert D., Dickstain K. et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27 (22): 2725–2736;
Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296(18):2217–26.
Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал сердечная недостаточность. 2014; 4 (1): 135–141;
Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114(8):625–30.
O"Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11(3):200–5;
Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic signiﬁcance. Eur Heart J 2014; 35: 1284–1293
Shepperd S, McClaran J, Phillips CO, et al. Discharge planning from hospital to home. Cochrane Database Syst Rev 2010;(1): CD000313
Bielecka-Dabrowa A, Godoy B, Schefold JC et al. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018 Aug; 15(4): 224-238
Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity-scoring methods. Intensive Care Med 2011; 37: 290 – 301.
Фомин И.В., Краием Н., Поляков Д.С., и др. Понятие стабильности течения ХСН – приемлемо ли оно для российской практики? Кардиология. 2018. Т. 58. - №. S3 - С.55- 63.]
Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail 7 (2005) 423– 428;
Shaﬁe AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018; 23(1):131-145
McAlister FA, Lawson FM, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001; 110: 378–84.3
Виноградова Н.Г., Жиркова М.М., Фомин И.В., Поляков Д.С. Эффективность лечения хронической сердечной недостаточности на амбулаторном этапе в условиях городского центра ХСН. Журнал сердечная недостаточность. -2017. -Т.18. № 4. -С.270- 278.
Фомин И.В., Виноградова Н.Г., Фарзалиев М.И., и др. Эффективность наблюдения пациентов в условиях специализированного центра лечения хронической сердечной недостаточности. Неотложная кардиология и кардиоваскулярные риски. 2018. Т. 2. - №.1. - С. 221-229. ISSN: 2616-633X20, 21
Виноградова Н.Г., Поляков Д.С., Фомин И.В., Жиркова М.М. Прогноз жизни пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в зависимости от контроля гемодинамических показателей и толерантности к физической нагрузке на фоне базисной терапии. Кардиология. 2019; 59 (4S): 51-58.
Виноградова Н.Г. Городской центр лечения хронической сердечной недостаточности: организация работы и эффективность лечения пациентов с хронической сердечной недостатосностью. Кардиология. 2019; 59 (2S): 31-39
Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010; (8):CD007228.
Koehler F., Winkler S., Schieber M., et al. Telemedial interventional monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure. Eur J Heart Fail. 2010; 12: 1354-1362.
Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178-187.
Linden A, Butterworth S. A comprehensive hospital-based intervention to reduce readmissions for chronically ill patients: a randomized controlled trial. Am J Manag Care. 2014; 20(10): 783-792.
Wakeﬁeld BJ, Boren SA, Groves PS, Conn VS. Heart failure care management programs: a review of study interventions and meta-analysis of outcomes. J Cardiovasc Nurs. 2013; 28(1): 8-19.
Van Spall HGC., Lee SF., Xie F., et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. The PACT-HF Randomized Clinical Trial. JAMA. 2019; 321 (8): 753-761. doi:10.1001/jama.2019.0710
Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure? Health Aff (Millwood). 2009; 28: 179–89.
Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017; 19(11): 1427-1443.
Masoudi FA. A Transitional-Care Model to Reduce Readmissions After Heart Failure? JAMA. 2019; 321, March 22: doi:10.1001/jama.2019.0710.
H.M. Krumholz, J. Amatruda, G.L Smith, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol, 39 (2002): 83-89;
S. Stewart, J.D. Horowitz. Home-based intervention in congestive heart failure: long- term implications on readmission and survival. Circulation, 105 (2002): 2861-2866
Беленков Ю. Н., Агеев Ф. Т., Банщиков Г. Т. и др. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы «Шанс» // Сердечная недостаточность. 2007; 3: 112– 116;
Фомин И.В., Виноградова Н.Г. Организация специализированной медицинской помощи больным с хроничекой сердечной недостаточностью. CardioСоматика. 2017. Т. 8. №3. С. 10-15.
Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154 (2):260–6. DOI:10.1016 / j. ahj. 2007.01.041//
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15 (7):808–17. DOI:10.1093 / eurjhf / hft050.
Fonarow G., Stough W., Abraham W., Albert N., Gheorghiade M., Greenberg B., O’Connor C., Sun J., Yancy C. and Young J. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007; 50(8):768-777. https://doi.org/10.1016/j.jacc.2007.04.064.
Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;8:e72476. doi: 10.1371/journal.pone.0072476.
Fonarow GC, Abraham WT, Albert NM; et al. Factors Identiﬁed as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes. Findings From OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-854. doi:10.1001/archinte.168.8.847.
Sandoval C, Walter SD, Krueger P, Smieja M, Smith A, Yusuf S, Loeb MB. Risk of hospitalization during inﬂuenza season among a cohort of patients with congestive heart failure.Epidemiol Infect. 2007; 135:574–582. doi: 10.1017/S095026880600714X
Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD; PARADIGM-HF Investigators. Inﬂuenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial.JACC Heart Fail. 2016; 4:152–158. doi: 10.1016/j.jchf.2015.10.012.
Mohseni H, Kiran A, Khorshidi R, Rahimi K. Inﬂuenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.Eur Heart J. 2017; 38:326–333. doi: 10.1093/eurheartj/ehw411.
Kopel E, Klempfner R, Goldenberg I. Inﬂuenza vaccine and survival in acute heart failure.Eur J Heart Fail. 2014; 16:264–270. doi: 10.1002/ejhf.14.
Modin, D, Jorgensen, ME, Gislason, G, Jensen, JS, Kober, L, Claggett, B, Hegde, SM, Solomon, SD, Torp-Pedersen, C, Biering-Sørensen, T. Inﬂuenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish Nationwide Cohort Study. Circulation. 2019:139:575–589. doi: 10.1161/CIRCULATIONAHA.118.036788.
Antunes MM, Duarte GS, Brito D, Borges M, Costa J, Ferreira JJ, Pinto FJ, Caldeira D, Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. European Heart Journal - Quality of Care and Clinical Outcomes, qcaa030, https://doi.org/10.1093/ehjqcco/qcaa030.
Renal syndromes associated with nonsteroidal antiinﬂammatory drugs. Clive DM, Stoff JS N Engl J Med. 1984 Mar 1; 310(9):563-72ю
Prostaglandins in severe congestive heart failure. Relation to activation of the renin-- angiotensin system and hyponatremia. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH N Engl J Med. 1984 Feb 9; 310(6):347-52.
Van den Ouweland FA, Gribnau FW, Meyboom RH Congestive heart failure due to nonsteroidal anti-inﬂammatory drugs in the elderly Age Ageing. 1988 Jan; 17(1):8-16.
Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti‐inﬂammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta‐analysis of Observational Studies Clin Cardiol. 2016 Feb; 39(2):111-8. Epub 2015 Dec 31.
Doukky R, Avery E, Mangla A, Collado FM, Ibrahim Z, Poulin M-F, et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC: Heart Failure. 2016;4 (1):24– 35. DOI:10.1016 / j. jchf. 2015.08.007
Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normalsodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clinical Science. 2008;114 (3):221–30. DOI:10.1042 / CS2007019
De Vecchis R, Paccone A , Di Maio M. Effects of a Restricted Water Intake on Various Clinical and Laboratory Outcomes in Patients With Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Minerva Cardioangiol. 2020 Feb 20. doi: 10.23736/S0026- 4725.20.05072-0. Online ahead of print.
Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan RS, et al. Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine. 2002;136 (3):181. DOI:10.7326 / 0003-4819-136-3-200202050-00005.
Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schafer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. Eur J Heart Fail 2017;19:821–836.
Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos AP. Deﬁning advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail 2016;22: 569– 577
Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW. Clinical assessment identiﬁes hemodynamic proﬁles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797–1804
Chakko S,Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM, Myerberg RJ. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conﬂicting results may lead to inappropriate care. Am J Med 1991;90:353–359
Hummel YM, Liu LCY, Lam CS, Fonseca-Munoz DF, Damman K, Rienstra M, van der Meer P, Rosenkranz S, van Veldhuisen DJ, Voors AA, Hoendermis ES. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail 2017;19:1651–1660
Quinones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM, Shelton BJ, Weiner DH. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: signiﬁcance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000;35:1237–1244;
Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, Cohn JN. Severity of left ventricular remodeling deﬁnes outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004;43:1892–1897
Rossi A, Cicoira M, Bonapace S, Golia G, Zanolla L, Franceschini L, Vassanelli C. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart 2007;93:1420–1425
Paraskevaidis IA, Ikonomidis I, Simitsis P, Parissis J, Stasinos V, Makavos G, Lekakis J. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study. Eur J Heart Fail 2017;19:846–861
Lichtenstein D, Lascols N, Mezière G, Gepner A: Ultrasound diagnosis of alveolar consolidation in the critically ill. Intensive Care Med 2004, 30:276–281;
Platz E, Lewis EF, Uno H, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J 2016;37:1244–51
Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299:2656–2666
Hawkins NM,Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart 2007;93: 59–64
Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, DeFilippi C, Harjola V-P, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre- hospital and early hospital management of acute heart failure: a consensus paper from the HFA of the ESC, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015;17:544–558
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987–1996
Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833–838
Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, Pitzus AE, Garcia EH, Obregon R, Brizuela M, Barbagelata A. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identiﬁcation. Circulation 2004;110:2376–2382.
Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101:231–7.
Peacock WFI, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26
Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943–1950
Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL. Soluble ST2, high-sensitivity troponin T- and N- terminal pro-B-type natriuretic peptide: complementary role for risk stratiﬁcation in acutely decompensated heart failure. Eur J Heart Fail 2011;13:718–725.
Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101:29–38.
Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19:507–19
van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006;98:386–90.
Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–74.
Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–41.
Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–33.
Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayés-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? Eur J Heart Fail 2015;17:936–944
Park M, Sangean MC, Volpe MDS, Feltrim MIZ, Nozawa E, Leite PF, Passos Amato MB, Lorenzi-Filho G. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med 2004;32:2407–2415
Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 2010;96:533–538
Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013;5: CD005351
Weng C-L, Zhao Y-T, Liu Q-H, Fu C-J, Sun F, Ma Y-L, Chen Y-W, He Q-Y. Meta- analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010;152:590–600
Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, Crane S, Elliott M, Nicholl J. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO Trial. Health Technol Assess 2009;13:1–106
Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669–674
Metra M, Felker GM, Zaca` V, Bugatti S, Lombardi C, Bettari L, Voors AA, Gheorghiade M, Dei Cas L. Acute heart failure: multiple clinical proﬁles and mechanisms require tailored therapy. Int J Cardiol 2010;144:175–179
Wakai A, McCabe A, Kidney R, B,rooks SC, Seupaul RA, Diercks DB, Salter N, Fermann GJ, Pospisil C. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013;8:CD005151
Ify R Mordi , Bernadet T Santema, Mariëlle Kloosterman , Anna-Maria Choy, Michiel Rienstra , Isabelle van Gelder , Stefan D Anker , John G Cleland , Kenneth Dickstein , Gerasimos Filippatos, Pim van der Harst, Hans L Hillege , Marco Metra , Leong L Ng , Wouter Ouwerkerk , Piotr Ponikowski , Nilesh J Samani Dirk J van Veldhuisen , Aeilko H Zwinderman , Faiez Zannad , Adriaan A Voors , Chim C Lang. Prognostic signiﬁcance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial ﬁbrillation. Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.
Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I, Richards M, Andersson B, Ezekowitz JA, Komajda M, Petrie MC, McAlister FA, Gamble GD, Whalley GA, McMurray JJ. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial ﬁbrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail 2015;17:1182–1191
Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial ﬁbrillation and ﬂutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521–528
Delle Karth G, Geppert A, Neunteuﬂ T, Priglinger U, Haumer M, Gеschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149–1153
Clemo H, Wood M, Gilligan D, Ellenbogen K. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594–598.
Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail 2015;3: 647–653.
Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 2017;19:1414–1423; Ertl G, Angermann CE, Bekeredjian R, Beyersdorf F, Güder G, Gummert J, Katus HA, Kindermann I, Pauschinger M, Perings S, Raake PWJ, Störk S, Scheidt Wv, Welz S, Böhm M. Aufbau und Organisation von Herzinsufﬁzienz-Netzwerken (HF-NETs) und Herzinsufﬁzienz-Einheiten (“Heart Failure Units”, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsufﬁzienz. Der Kardiologe 2016;10:222–235
Voors AA, OuwerkerkW, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Ng LL, Metra M, Ter Maaten JM, Lang CC, Hillege HL, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Zwinderman AH. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 2017;19:627–634
Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol 2003;92:1350–1354
Wachter R Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, Al Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients inhospital or early after discharge: Primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019 doi:10.1002/ejhf.1498
Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratiﬁcation for inhospital mortality in acutely decompensated heart failure classiﬁcation and regression tree analysis. JAMA 2015;293:572–580
Thorvaldsen T, Benson L, Stahlberg M, Dahlstrom U, Edner M, Lund LH. Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center? J Am Coll Cardiol 2014;63:661–671.
Jonkman NH, Westland H, Groenwold RH, Ågren S, Atienza F, Blue L, Bruggink-André de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T, Kempen GI, Leventhal ME, Lok DJ, Mårtensson J, Muñiz J, Otsu H, Peters-Klimm F, Rich MW, Riegel B, Strömberg A, Tsuyuki RT, van Veldhuisen DJ, Trappenburg JC, Schuurmans MJ, Hoes AW. Do Self-Management Interventions Work in Patients With Heart Failure? An Individual Patient Data Meta- Analysis. Circulation. 2016 Mar 22;133:1189-98
Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883-1890
Iakobishvili Z, Cohen E, Garty M, Behar S, Shotan A, Sandach A, Gottlieb S, Mager A, Battler A, Hasdai D. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care 2011;13:76–80
Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008;25:205–209
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–1540
Felker GM, Lee KL, Bull DA, Redﬁeld MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Oﬁli EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide- type diuretics in heart failure. J Am Coll Cardiol 2010;56:1527–1534
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent J-L. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779–789.
Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541–1547
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103–111
O’Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138(1 Pt 1):78–86
Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail 2017;4:595–604
Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, Zangrillo A, Landoni G. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 2015;115:656–675
Dentali F, Douketis JD, Gianni M, LimW, Crowther M. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278–288
Sintek MA, Gdowski M, Lindman BR, Nassif M, Lavine KJ, Novak E, Bach RG, Silvestry SC, Mann DL, Joseph SM. Intra-aortic balloon counterpulsation in patients with chronic heart failure and cardiogenic shock: clinical response and predictors of stabilization. J Card Fail 2015;21:868–876; Saffarzadeh A, Bonde P. Options for temporary mechanical circulatory support. J Thorac Dis 2015;7:2102–2111
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med. 2017;376:451-460.
Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya M, Salerno C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA, Estep JD, Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER, O"Connell JB, Heatley G, Sood P, Naka Y; MOMENTUM 3 Investigators. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378:1386-1395.
John R, Long JW, Massey HT, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg. 2011; 141(4):932-939.
Riebandt J, Haberl T, Mahr S, Laufer G, Rajek A, Steinlechner B, Schima H, Zimpfer D. Preoperative patient optimization using extracorporeal life support improves outcomes of INTERMACS Level I patients receiving a permanent ventricular assist device. Eur J Cardiothorac Surg. 2014 Sep; 46(3):486-92; discussion 492. doi: 10.1093/ejcts/ezu093. Epub 2014 Mar 18
Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения хронической сердечной недостаточности. -М.: Медиа Медика; 2000. 266 с.
Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919
Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783–5.
Faggiano P, D’Aloia A, Gualeni A, Brentana L, Cas LD. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail. 2004;6(6):687–91.
Zielińska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic value of the six-minute walk test in heart failure patients undergoing cardiac surgery: a literature review. Rehabil Res Pract. 2013; doi: 10.1155/2013/965494.
Ingle L, Cleland JG, Clark AL. The long-term prognostic signiﬁcance of 6-minute walk test distance in patients with chronic heart failure. Biomed Res Int. 2014;2014:505969
Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med. 2014;57(4):244–53
Pollentier B, Irons SL, Benedetto CM, DiBenedetto AM, Loton D, Seyler RD, et al. Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. Cardiopulm Phys Ther J. 2010;21(1):13–21
Palau P, Domínguez E, Núñez E, Sanchis J, Santas E, Núñez J. Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: useful for functional capacity assessment? Int J Cardiol. 2016;203:800–2
Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM, McKelvie RS, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol. 2012;60(25):2653–61
Kaminsky LA, Tuttle MS. Functional assessment of heart failure patients. Heart Fail Clin. 2015;11(1):29–36